Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Small Biopharmas Should Be Wary Of Early Results – US FDA Official

Executive Summary

Two former Genzyme execs, one of whom now works at CDER, warn small companies to avoid over-emphasizing results from early, uncontrolled trials in their planning and business decision-making.


Related Content

Moscicki, One Of US FDA's Industry Connections, Moves To PhRMA
Carrots and Stick: Biopharma At The White House
No More Sarepta-Like Development, FDA Officials Say
Eteplirsen Review Offers Lessons For FDA, Advocacy Groups, Industry
Sarepta's Eteplirsen Approved After Contentious Internal FDA Debate
CDER Taps Genzyme Exec As Deputy Director For Science Operations


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts